Anupam Rasayan India Ltd. · NSE:ANURAS
Anupam Rasayan India — Q4 FY23 Earnings Presentation
30 slides from Anupam Rasayan India's earnings presentation, May 3, 2023
Slide 1: Stock exchange cover letter: Investor Presentation
ANUPAM RASAYAN INDIA LTD. R ARILSLDSTX20230503014 Date: May 03, 2023 To, To, BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, ‘Exchange Plaza’, C-1, Block-G, Dalal Street, Bandra Kurla Complex Mumbai -400001, India Bandra (East), Mumbai 400051, India SCRIP CODE: 54327
Slide 2: Anupam Rasayan India Limited Investor Presentation Q4FY23 & FY23
ANUPAM RASAYAN INDIA LIMITED INVESTOR PRESENTATION BSE: 543275 | NSE: ANURAS | ISIN: INE930P01018 Q4FY23 & FY23 ©2020 – Anupam Rasayan India Limited, All Rights Reserved. May 2023
Slide 3: Financials and Operational Updates
FINANCIALS AND OPERATIONAL UPDATES
Slide 4: Yearly Financial Highlights
Yearly Financial Highlights Standalone Operating Revenue was Standalone EBITDA (Incl. Other Standalone PAT stood at ₹ 1,685 ₹ 12,841 Mn; Y-o-Y growth of 20% Revenue) was ₹ 3,697 Mn.; Y-o-Y Mn., Y-o-Y growth of 12% growth of 19% Consolidated Operating Revenue Consolidated EBITDA (Incl. Other Consolid
Slide 5: Managing Director's Message
Managing Director’s Message Mr. Anand S Desai "It gives me pleasure to share that we have continued our growth momentum with a 49% YoY M A N A G I N G D I R E C TO R revenue growth on the back of new products commercialized during the year as well as steady growth of the organic portfolio. On the op
Slide 6: Operational Updates
Operational Updates • New LOI’s Signed – In last 2 months, we have signed LOI’s worth ₹28,640 Mn with Japanese and American MNCs for niche life sciences and specialty chemical molecules. These LOI’s demonstrates the increasing confidence of global MNCs in our technical capabilities and sustainable s
Slide 7: Operational Updates
Operational Updates • Financial Performance - During the FY23, company generated operating cash flow of ₹2,440 Mn owing to higher profitability and improvement in working capital cycle. • Capex Incurred – Company incurred capex of ₹644 Mn in FY23 out of the ₹6,700 Mn announced, with majority of the
Slide 8: Standalone Financial Ratios
Standalone Financial Ratios CAGR CAGR CAGR 24% 30% 55% 14,000 4,000 1,800 3,500 1,600 12,000 1,400 10,000 3,000 1,200 2,500 8,000 1,000 2,000 10,811 12,863 6,000 800 1,508 1,685 8,373 2,202 3,111 3,697 1,500 600 4,000 703 1,000 400 2,000 500 200 - - - FY21 FY22 FY23 FY21 FY22 FY23 FY21 FY22 FY23 Rev
Slide 9: Consolidated Financial Ratios
Consolidated Financial Ratios CAGR CAGR CAGR 39% 41% 76% 18,000 5,000 2,500 16,000 14,000 4,000 2,000 12,000 3,000 1,500 10,000 10,811 16,105 8,000 1,000 1,522 2,168 2,000 8,375 3,121 4,399 2,202 6,000 703 4,000 1,000 500 2,000 - - - FY21 FY22 FY23 FY21 FY22 FY23 FY21 FY22 FY23 Revenue (₹ Mn.) EBITD
Slide 10: Strong Order Book – Recent LOI/Contracts Signed
Strong Order Book – Recent LOI/Contracts Signed Signing Quarter Segment Customer LOI/Contract Tenor (Years) Value(₹ Crores) Multinational Life Science Q1FY22 Life Science LOI 5 ₹1,100 Company Q1FY22 Life Science Two Multinational Companies Contract 5 ₹540 European Multinational Q2FY22 Life Science C
Slide 11: Standalone Profit & Loss Summary
YEARLY FINANCIALS Standalone Profit & Loss Summary (All amounts are in ₹ Mn) FY22 FY23 INCOME Revenue from Operations 10,738 12,841 Other Income 73 22 Total Revenue 10,811 12,863 Total Revenue Growth (%) 20% EXPENSES: Cost of Raw Materials Consumed 3,712 5,134 Gross Profit 7,026 7,707 Gross Margins
Slide 12: Consolidated Profit & Loss Summary
YEARLY FINANCIALS Consolidated Profit & Loss Summary (All amounts are in ₹ Mn) FY22 FY23 INCOME Revenue from Operations 10,738 16,019 Other Income 73 86 Total Revenue 10,811 16,105 Total Revenue Growth (%) 49% EXPENSES: Cost of Raw Materials Consumed 3,699 7,036 Gross Profit 7,039 8,983 Gross Margin
Slide 13: Standalone Profit & Loss Summary (Quarterly)
QUARTERLY FINANCIALS Standalone Profit & Loss Summary (All amounts are in ₹ Mn) Q4FY22 Q4FY23 INCOME Revenue from Operations 3,249 3,713 Other Income (81) 180 Total Revenue 3,169 3,893 Total Revenue Growth (%) 23% EXPENSES: Cost of Raw Materials Consumed 1,032 1,735 Gross Profit 2,217 1,978 Gross Ma
Slide 14: Consolidated Profit & Loss Summary (Quarterly)
QUARTERLY FINANCIALS Consolidated Profit & Loss Summary (All amounts are in ₹ Mn) Q4FY22 Q4FY23 INCOME Revenue from Operations 3,249 4,800 Other Income (81) 243 Total Revenue 3,169 5,042 Total Revenue Growth (%) 59% EXPENSES: Cost of Raw Materials Consumed 1,028 2,359 Gross Profit 2,222 2,441 Gross
Slide 15: Our Business
OUR BUSINESS
Slide 16: About Anupam
About Anupam COMPANY AT A GLANCE Established Custom Synthesis player Specializes in multi-step Catering to globally relevant Strong supply chain with backward with 39 years of track record synthesis undertaking complex chemical & agrochemical integrated facilities chemical reactions to produce key c
Slide 17: Business Verticals & Customers
Business Verticals & Customers BUSINESS VERTICALS OVERVIEW FEW OF OUR TOP GLOBAL CLIENTS Life Science Related Other Specialty Specialty Chemicals Chemicals Agrochemicals Specialty Pigments (including Crop Protection) Manufacturing agro intermediates and agro active ingredients (insecticides, Special
Slide 18: Making a Mark Globally
Making a Mark Globally MANUFACTURING CLIENTELE UNITS IN INDIA GLOBALLY (In Nos.) (In Nos.) 6* 71* REVENUE BY GEOGRAPHY EUROPE 26% EUROPE 30% EUROPE 28% INDIA 44% INDIA 36% INDIA 42% SINGAPORE 11% SINGAPORE 11% FY21 SINGAPORE 10% FY22 JAPAN 12% FY23 JAPAN 16% JAPAN 15% CHINA 4% CHINA 4% CHINA 4% NORT
Slide 19: Evolution of Anupam
Evolution of Anupam Phase I-Inception Phase II- The Acceleration • Started working with • Raised ₹5,000 mn. • Fast growing • Formed • Started supplying • Awarded ‘Green • Commercialized 2 through QIP Specialty Chemical partnership firm to Syngenta Innovation Award’ more Adama Manufacturer with “Anup
Slide 20: Strong Manufacturing and R&D Capabilities
Strong Manufacturing and R&D Capabilities Manufacturing prowess R&D Competencies • DSIR recognized R&D center with a team of 88 R&D professionals ~27,200 MT Manufacturing Capacity, spread over 6 manufacturing facilities • Expertise in executing complex chemistries & multi step synthesis • Deployed f
Slide 21: Key ESG Initiatives
Key ESG Initiatives • Company has switched to cleaner source of electricity generation and utilization by installing the 17.9 MW solar power plant at Bharuch District. This will significantly reduce scope 2 emissions. • Submitting Business Responsibility and Sustainability Report on voluntary basis
Slide 22: Growth Drivers
Growth Drivers Growth of Product Execution of Signed LOIs Expansion in Portfolio and Contracts Fluorination chemistry ANUPAM RASAYAN INDIA LIMITED | 21
Slide 23: Growth Of Product Portfolio
Growth Of Product Portfolio NUMBER OF MOLECULES IN NUMBER OF MOLECULES TO R&D AND PILOT BE COMMERCIALISED IN FY24 90+ 10+ New Strategic Custom Development Products under pipeline to be manufactured by Anupam in India: Agro: • Established Active Ingredients of originators which are currently being ma
Slide 24: Anupam – Tanfac Integration
Anupam – Tanfac Integration Anupam acquired ~26% stake in Tanfac for ~₹1,530M in May'22 Backward integration with Tanfac to secure KSM Uninterrupted access to key raw materials (HF and KF) for fluorination chemistry Only Indian Producer of manufacturer of Leading producer fluorinated niche molecules
Slide 25: Expansion in Fluorination chemistry
Expansion in Fluorination chemistry Details of Few Molecules out of 14 Identified Segment Revenue Focused Segments Molecules End Application Customer Potential Product A Elastomer US MNC Polymers $ 40 – 70 Mn. Semiconductor/Flame Product B Japanese MNC Retardant Product X/Y Cardio/Anti-viral Indian
Slide 26: Experienced Leadership & Deep Technical Talent Pool
Experienced Leadership & Deep Technical Talent Pool Experienced management team Our R&D talent pool Mr. Anand Desai Ms. Mona A Desai Image here Managing Director Over 30 years of experience in Image here Vice- Chairman & Whole- Time Director 88+ 175+ chemicals industry associated Over 20 years of ex
Slide 27: Expanded Business Development Team
Expanded Business Development Team Europe Mr. Thierry Baumlin Mr. Mauro Principe Mr. Pierre Joris Mr. Oliver Kappe Key Account Manager – Europe Business Development – Fluoro Business Advisor Technical Advisor – Flow Business – Europe Chemistry 30 years+ of experience in 30 years+ of experience in Ch
Slide 28: Board of Directors
Board of Directors DR. KIRAN C PATEL MR. ANAND S DESAI MS. MONA A DESAI MR. MILAN THAKKAR CHAIRMAN & MANAGING DIRECTOR VICE-CHAIRMAN & NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR WHOLE-TIME DIRECTOR • Associated with the company for past • Over 30 years of experience in • Over 20 years of experien
Slide 29: Safe Harbor
Safe Harbor Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's results may
Slide 30: Thank You
THANK YOU CONTACT US: MR. VISHAL THAKKAR MR. RAVISH CHAUDHARY Anupam Rasayan India Ltd. investors@anupamrasayan.com MR. RAHUL THKUR MR. DIWAKAR PINGLE EY Investor Relations Rahul.thakur@in.ey.com diwakar.pingle@ey.com CORPORATE OFFICE Anupam Rasayan India Ltd. India (HQ) 8110, Sachin G.I.D.C. Estate